Skip to main content

Table 2 SUVmax and RI-SUV at each time point in each group

From: Preliminary clinical assessment of dynamic carbon-11 methionine positron-emission tomography/computed tomography for the diagnosis of the pathologies in patients with musculoskeletal lesions: a prospective study

Group BMSL MMSL PMMST MMST ML MMST and ML
SUV1 2.58 ± 0.50 (1.13–3.73) 6.04 ± 0.66 (4.36–11.42) 5.00 ± 0.75 (4.36–8.51) 6.04 ± 0.49 (4.86–8.51) 10.09 ± 1.12 (7.59–11.42) 7.15 ± 0.90 (4.86–11.42)
SUV2 2.18 ± 0.42 (1.07–3.41) 6.35 ± 0.89 (4.19–13.45) 4.41 ± 1.03 (4.19–9.58) 6.35 ± 0.53 (5.63–8.09) 11.91 ± 1.34 (8.90–13.45) 8.09 ± 1.13 (5.63–13.45)
SUV3 1.77 ± 0.34 (1.00–2.97) 6.69 ± 1.05 (3.57–14.90) 4.30 ± 1.11 (3.57–9.66) 6.69 ± 0.63 (6.33–9.03) 13.52 ± 1.85 (8.80–14.90) 8.80 ± 1.31 (6.33–14.90)
SUV4 1.56 ± 0.32 (1.01–2.86) 7.27 ± 1.08 (3.53–14.80) 4.25 ± 1.22 (3.53–10.13) 7.27 ± 0.89 (6.23–10.28) 13.57 ± 1.59 (9.55–14.80) 9.55 ± 1.25 (6.23–14.80)
SUV5 1.49 ± 0.27 (1.11–2.62) 7.81 ± 1.28 (3.38–18.49) 4.39 ± 1.33 (3.38–10.72) 7.81 ± 0.88 (6.97–10.94) 13.21 ± 2.44 (10.14–18.49) 10.14 ± 1.53 (6.97–18.49)
SUV6 1.41 ± 0.30 (1.03–2.75) 8.41 ± 1.26 (3.47–17.21) 4.22 ± 1.24 (3.47–10.23) 8.41 ± 0.84 (7.63–11.34) 15.07 ± 2.23 (9.72–17.21) 9.72 ± 1.40 (7.63–17.21)
RI-SUV − 26.27 ± 12.55 (− 50.00 to 23.6) 30.01 ± 9.34 (− 28.89 to 70.57) − 7.11 ± 8.06 (− 28.89 to 20.21) 48.35 ± 7.29 (34.57–63.79) 31.96 ± 13.57 (28.06–70.57) 38.10 ± 6.53 (28.06–70.57)
  1. The data represent the median ± standard error of the mean; data in parentheses are the ranges
  2. SUV standardised uptake value, RI-SUV retention index of maximum standardised uptake value, BMSL benign musculoskeletal lesion, MMSL malignant musculoskeletal lesion, PMMST primary malignant musculoskeletal tumour, MMST metastatic musculoskeletal tumour, ML malignant lymphoma